Editor Note: For more information about this release, please scroll to bottom
LONDON, August 14, 2013 /PRNewswire/ --
The U.S. equity market ended higher on Tuesday, August 13, 2013, after finishing on a mixed note in the previous trading session. The S&P 500 rose 0.28% to close at 1,694.16. The biotechnology companies ended mostly lower, even as the broader market edged higher. The major movers in the sector included BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), PDL BioPharma Inc. (NASDAQ: PDLI), and Amgen Inc. (NASDAQ: AMGN). AAAResearchReports.com has released full comprehensive research on BCRX, QCOR, PDLI, and AMGN. These free technical analyses can be downloaded by signing up at:
Shares in BioCryst Pharmaceuticals Inc. fell sharply on Tuesday, even as the broader market posted gains. The company's shares closed the day 2.31% lower at $5.50 after oscillating between $5.43 and $5.71. A total of 1.32 million shares were traded which is below the daily average volume of 3.54 million. BioCryst Pharmaceuticals Inc.'s shares have gained 203.87% in the last three months, as compared to a gain of 3.70% in the S&P 500 during the same period. Moreover, the company's shares are trading above their 50-day and 200-day moving averages. Download free report on BCRX upon registration at:
Shares in Questcor Pharmaceuticals Inc. surged on Tuesday, tracking gains in the broader market. The company's shares oscillated between $66.25 and $69.33 before finishing the day 4.40% higher at $69.05. A total of 1.93 million shares were traded which is marginally above the daily average volume of 1.92 million. Questcor Pharmaceuticals' shares have gained 40.06% in the last one month and 84.13% in the last three months, outperforming the S&P 500 which has gained 0.83% and 3.70% in the respective periods. Moreover, the stock is currently trading near its 52-week high of $70.55. QCOR technical report can be accessed for free by signing up at:
PDL BioPharma Inc.'s shares fluctuated between $8.34 and $8.45 on Tuesday before ending the day 0.36% lower at $8.41. A total of 1.67 million shares were traded which is below the daily average volume of 1.84 million. The company's shares have gained 3.44% during the last three trading sessions, and 3.70% in the last three months. Despite Tuesday's pullback, the stock is trading near its 52-week high of $8.48, and also above its 50-day and 200-day moving averages. The free report on PDLI can be downloaded by signing up now at:
Amgen Inc.'s stock ended slightly lower on Tuesday, finishing at $107.86, down 0.32% from its previous closing price. The company's shares oscillated between $107.03 and $108.92. A total of 2.68 million shares were traded which is below the daily average volume of 3.22 million. The stock has gained 3.44% in the last one month, outperforming the S&P 500 which has gained 0.83% during the same period. Additionally, the stock is trading above its 50-day and 200-day moving averages. A free report on AMGN can be accessed by registering at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA ® charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
SOURCE AAA Research Reports